维生素D对妊娠糖尿病患者血清脂肪因子及C反应蛋白水平的影响  

Effect of vitamin D on serum adipokine and C-reactive protein levels in patients with gestational diabetes mellitus

作　　者：孟静[1] 孔芹[1] MENG Jing;KONG Qin(Department of Obstetrics,Tengzhou Central People's Hospital,Tengzhou 277599,Shandong Procvinve,China)

机构地区：[1]滕州市中心人民医院产科,山东滕州277599

出　　处：《中国临床药理学杂志》2020年第16期2394-2396,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察维生素D对妊娠糖尿病(GDM)患者血清脂肪因子及C反应蛋白(CRP)水平的影响。方法将GDM患者200例随机分为对照组和试验组,各100例。对照组给予门冬胰岛素0.3~0.4 U·kg-1·d-1,餐前皮下注射;试验组在对照组的基础上给予维生素D 0.25μg·d-1,口服。2组均连续治疗30 d。比较2组患者治疗前后空腹血糖(FBG)、空腹胰岛素(FINS)水平、胰岛素抵抗指数(HOMA-IR)、血清脂联素(APN)、内脂素(visfatin)及瘦素(leptin)水平及血清CRP水平。比较2组患者治疗期间的药物不良反应发生情况。结果治疗后,对照组与试验组FBG分别为(6.31±0.87),(5.18±0.82)mmol·L-1;FINS水平分别为(6.37±0.46),(4.25±0.39)μU·mL-1;HOMA-IR分别为1.92±0.55,1.21±0.37;血清APN水平分别为(8.23±1.51),(11.64±2.76)mg·L-1;内脂素水平分别为(47.11±8.72),(36.21±7.67)μg·L-1;瘦素水平分别为(28.92±3.43),(21.37±4.29)μg·L-1;血清CRP水平分别为(5.27±2.36),(3.52±1.56)mg·L-1,差异均有统计学意义(均P<0.05)。对照组与试验组的药物不良反应发生率分别为2.0%,3.0%,差异无统计学意义(P>0.05)。结论维生素D可改善GDM患者糖代谢紊乱,调节脂肪因子水平,同时降低血清CRP水平,抑制炎症反应,且安全性较高。Objective To investigate the effect of vitamin D on serum adipokine and C-reactive protein(CRP) levels in patients with gestational diabetes mellitus(GDM). Methods A total of 200 GDM patients were randomly divided into control group and treatment group, with 100 cases in each group. Control group was given insulin aspart, 0.3-0.4 U·kg-1·d-1, subcutaneously before meals;treatment group was given vitamin D 0.25 μg·d-1, oral, on the basis of control gorup. Both groups were treated for 30 d. The fasting blood glucose(FBG), fasting insulin(FINS) levels, Homeostasis model assessment of insulin resistance(HOMA-IR), serum adiponectin(APN), visfatin, leptin levels and serum CRP levels in two groups were compared before and after treatment. The incidence of adverse drug reactions during treatment between the two groups were compared. Results After treatment, the levels of FBG in control group and treatment group were(6.31±0.87),(5.18±0.82) mmol·L-1;FINS levels were(6.37±0.46) and (4. 25 ± 0. 39) μU · mL-1;HOMA-IR were 1. 92 ± 0. 55 and 1. 21 ± 0. 37;the serum APN levels were(8. 23 ± 1. 51) and(11. 64 ± 2. 76) mg·L-1;the levels of visfatin were(47. 11 ± 8. 72) and(36. 21 ± 7. 67)μg·L-1;the levels of leptin were(28. 92 ± 3. 43) and(21. 37 ± 4. 29) μg ·L-1;the serum CRP levels were(5. 27 ± 2. 36) and(3. 52 ± 1. 56) mg·L-1,all with significant difference(all P < 0. 05). The incidence of adverse drug reactions in control group and treatment group were 2. 0% and 3. 0%,with no significant difference(P > 0. 05).Conclusion Vitamin D can improve glucose metabolism disorders,regulate adipokine levels,reduce serum CRP levels,and inhibit inflammatory responses in patients with GDM,and thus play a role in treating GDM,with good safety.

关 键 词：妊娠糖尿病 维生素D 脂肪因子 C反应蛋白 

分 类 号：R97[医药卫生—药品]